PFE
Income statement / Annual
Last year (2025), Pfizer Inc.'s total revenue was $62.58 B,
a decrease of 1.65% from the previous year.
In 2025, Pfizer Inc.'s net income was $7.77 B.
See Pfizer Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$62.58 B |
$63.63 B |
$59.55 B |
$101.18 B |
$81.29 B |
$41.65 B |
$40.91 B |
$40.83 B |
$52.55 B |
$52.82 B |
| Cost of Revenue |
$16.07 B
|
$17.85 B
|
$24.95 B
|
$34.34 B
|
$30.82 B
|
$8.48 B
|
$8.05 B
|
$8.99 B
|
$11.23 B
|
$12.32 B
|
| Gross Profit |
$46.51 B
|
$45.78 B
|
$34.60 B
|
$66.83 B
|
$50.47 B
|
$33.17 B
|
$32.85 B
|
$31.84 B
|
$41.32 B
|
$40.50 B
|
| Gross Profit Ratio |
0.74
|
0.72
|
0.58
|
0.66
|
0.62
|
0.8
|
0.8
|
0.78
|
0.79
|
0.77
|
| Research and Development Expenses |
$10.44 B
|
$10.82 B
|
$10.68 B
|
$11.43 B
|
$13.83 B
|
$9.39 B
|
$8.39 B
|
$7.76 B
|
$7.68 B
|
$7.89 B
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.79 B
|
$14.73 B
|
$14.77 B
|
$13.68 B
|
$12.70 B
|
$11.60 B
|
$12.73 B
|
$12.61 B
|
$14.80 B
|
$14.84 B
|
| Other Expenses |
$4.87 B
|
$5.29 B
|
$4.73 B
|
$3.61 B
|
$3.70 B
|
$3.35 B
|
$4.43 B
|
$4.74 B
|
$4.76 B
|
$4.06 B
|
| Operating Expenses |
$29.11 B
|
$30.84 B
|
$30.18 B
|
$28.71 B
|
$30.23 B
|
$24.34 B
|
$25.54 B
|
$25.11 B
|
$27.25 B
|
$26.79 B
|
| Cost And Expenses |
$45.17 B
|
$48.69 B
|
$55.14 B
|
$63.06 B
|
$61.05 B
|
$32.82 B
|
$33.59 B
|
$34.10 B
|
$38.47 B
|
$39.11 B
|
| Interest Income |
$603.00 M
|
$545.00 M
|
$1.62 B
|
$251.00 M
|
$36.00 M
|
$73.00 M
|
$225.00 M
|
$333.00 M
|
$391.00 M
|
$470.00 M
|
| Interest Expense |
$2.67 B
|
$3.09 B
|
$2.21 B
|
$1.24 B
|
$1.29 B
|
$1.45 B
|
$1.57 B
|
$1.32 B
|
$1.27 B
|
$1.19 B
|
| Depreciation & Amortization |
$6.59 B
|
$7.01 B
|
$6.29 B
|
$5.06 B
|
$5.19 B
|
$4.78 B
|
$5.76 B
|
$6.15 B
|
$6.27 B
|
$5.76 B
|
| EBITDA |
$16.78 B |
$18.13 B |
$9.56 B |
$41.03 B |
$30.79 B |
$13.26 B |
$18.65 B |
$11.06 B |
$19.84 B |
$15.29 B |
| EBITDA Ratio |
0.27
|
0.28
|
0.16
|
0.41
|
0.38
|
0.32
|
0.46
|
0.27
|
0.38
|
0.29
|
| Operating Income Ratio |
0.28
|
0.23
|
0.07
|
0.38
|
0.25
|
0.21
|
0.18
|
0.16
|
0.27
|
0.26
|
| Total Other Income/Expenses Net |
-$9.89 B
|
-$6.92 B
|
-$3.36 B
|
-$3.39 B
|
$4.08 B
|
-$1.79 B
|
$4.01 B
|
-$3.14 B
|
-$1.77 B
|
-$5.36 B
|
| Income Before Tax |
$7.52 B
|
$8.02 B
|
$1.06 B
|
$34.73 B
|
$24.31 B
|
$7.04 B
|
$11.32 B
|
$3.59 B
|
$12.31 B
|
$8.35 B
|
| Income Before Tax Ratio |
0.12
|
0.13
|
0.02
|
0.34
|
0.3
|
0.17
|
0.28
|
0.09
|
0.23
|
0.16
|
| Income Tax Expense |
-$266.00 M
|
-$28.00 M
|
-$1.12 B
|
$3.33 B
|
$1.85 B
|
$370.00 M
|
$583.00 M
|
-$266.00 M
|
-$9.05 B
|
$1.12 B
|
| Net Income |
$7.77 B
|
$8.03 B
|
$2.12 B
|
$31.37 B
|
$21.98 B
|
$9.16 B
|
$16.03 B
|
$11.15 B
|
$21.31 B
|
$7.22 B
|
| Net Income Ratio |
0.12
|
0.13
|
0.04
|
0.31
|
0.27
|
0.22
|
0.39
|
0.27
|
0.41
|
0.14
|
| EPS |
1.36 |
1.42 |
0.3755 |
5.5929 |
3.9539 |
1.6488 |
2.9219 |
1.8992 |
3.5685 |
1.18 |
| EPS Diluted |
1.36 |
1.41 |
0.3712 |
5.471 |
3.8798 |
1.6262 |
2.8675 |
1.866 |
3.5168 |
1.17 |
| Weighted Average Shares Out |
$5.68 B
|
$5.66 B
|
$5.64 B
|
$5.61 B
|
$5.60 B
|
$5.56 B
|
$5.57 B
|
$5.87 B
|
$5.97 B
|
$6.09 B
|
| Weighted Average Shares Out Diluted |
$5.69 B
|
$5.70 B
|
$5.71 B
|
$5.73 B
|
$5.71 B
|
$5.63 B
|
$5.68 B
|
$5.98 B
|
$6.06 B
|
$6.16 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
